Pfizer partners with Chai Discovery on AI-driven drug development
Pfizer (PFE) has entered into an agreement with Chai Discovery to utilize its generative AI platform for discovering new treatments. The partnership aims to leverage advanced artificial intelligence in molecular interaction prediction and reprogramming, potentially accelerating the drug discovery process.
Tickers: $PFE
Topics: AI in Drug Discovery Pharmaceuticals